🇺🇸 FDA

Intelligence Platform

Patents

Browse 763 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 10618967

Anti-CSF1R antibody and anti PD-1 antibody combination therapy for cancer

Five Prime Therapeutics, Inc. · Granted Tue Apr 14 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 09 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10610535

Diarylpropionitrile therapy for treatment of multiple sclerosis

The Regents of the University of California · Granted Tue Apr 07 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 02 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10576096

Tumor-selective combination therapy

The Board of Regents of the University of Texas System · Granted Tue Mar 03 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 27 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10568873

Safranal-sorafenib combination therapy for liver cancer

UNITED ARAB EMIRATES UNIVERSITY · Granted Tue Feb 25 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 20 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10568963

Multifunctional nanoplatforms for fluorescence imaging and photodynamic therapy developed

THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Tue Feb 25 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 20 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10544223

Combination therapy with an anti-axl antibody-drug conjugate

ADC THERAPEUTICS SA · Granted Tue Jan 28 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 23 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10543222

Therapy for inhibition of single-stranded RNA virus replication

RedHill Biopharma Ltd. · Granted Tue Jan 28 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 23 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10537595

Processes for production of tumor infiltrating lymphocytes and uses of same in immunothera

Iovance Biotherapeutics, Inc. · Granted Tue Jan 21 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 16 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10537635

Detection of arginine methylation of EGFR for prediction of resistance to therapy

The Board of Regents of the University of Texas System · Granted Tue Jan 21 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 16 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10533227

Compositions, kits, and methods for identification, assessment, prevention and therapy of

The Board of Regents of the University of Texas System · Granted Tue Jan 14 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 09 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10526414

Use of anti-semaphorin-4D antibodies in combination with an immune modulating therapy to i

VACCINEX, INC. · Granted Tue Jan 07 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 02 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10525104

Predictive and prognostic biomarkers related to anti-angiogenic therapy of metastatic colo

REGENERON PHARMACEUTICALS, INC. · Granted Tue Jan 07 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 02 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10517948

Anti-DC-HIL antibodies for cancer diagnosis, prognosis and therapy

The Board of Regents of the University of Texas System · Granted Tue Dec 31 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 26 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10493162

Somatostatin receptor-based cancer therapy

The Board of Regents of the University of Texas System · Granted Tue Dec 03 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 28 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10488416

Targeting breast cancer therapy based on stromal subtypes and CD146 composition

The Regents of the University of Colorado, a Body Corporate · Granted Tue Nov 26 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 21 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10485886

Core-satellite nanocomposites for MRI and photothermal therapy

THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Tue Nov 26 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 21 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10471142

Combination therapy using immunoglobulin and C1-Inhibitor

THE GOVERNMENT OF THE UNITED STATES OF AMERICA · Granted Tue Nov 12 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 07 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10463734

Nanoparticle therapy in cancer

THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Tue Nov 05 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 31 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10463697

Processes for production of tumor infiltrating lymphocytes and uses of same in immunothera

Iovance Biotherapeutics, Inc. · Granted Tue Nov 05 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 31 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10451610

Prediction of response to PARP inhibitors and combinational therapy targeting C-MET and PA

The Board of Regents of the University of Texas System · Granted Tue Oct 22 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 17 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10449232

Puma protein expression vector and use thereof in gene therapy

The Regents of the University of California · Granted Tue Oct 22 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 17 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10441645

MSLN targeting DNA vaccine for cancer immunotherapy

Vaximm AG · Granted Tue Oct 15 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 10 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10435461

Therapy for filovirus infection

The Government of the United States, as represented by the Secretary of the Army · Granted Tue Oct 08 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 03 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10426797

Compositions and methods for treating cancer with anti-CD33 immunotherapy

United State of America, As Represented by the Secretary, Dept. of Health and Human Services · Granted Tue Oct 01 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 26 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted